NVS
NOVARTIS AGPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 10 Keri Sue Paddock, et al. v. Novartis Pharmaceuticals…
- Jun 30 ▲ 5 funds open new positions (13F)
- Jul 1 Novartis Pharmaceuticals Corp. v. Catherine L. Hanaway
- Jul 28 to Aug 4 2 court rulings: Regents of University of Michigan et al v. Novartis…; NOVARTIS AG et al v. NOVADOZ PHARMACEUTICALS LLC et al
- Aug 5 HSR Early Termination: Novartis AG; Myricx Pharma Limited
- Sep 1 ▲ Novartis announced positive Phase III topline results for remibrutin…
- Sep 4 ▼ Novartis announced that its Phase III Lp(a)HORIZON trial for pelacar…
- Oct 13 to Oct 15 2 court rulings: GENENTECH, INC. v. NOVARTIS PHARMA AG; ISAACS v. NOVARTIS PHARMACEUTICALS CORPORATION
- Oct 27 Novartis reported Q3 2026 net sales of USD 14.5 billion (+4% cc) and…
- Oct 30 ▼ Deutsche Bank downgrades
- Nov 9 Trial readout: T-90d Trial Readout: LXH254 (Phase 2)
- Nov 10 HSR Early Termination: Novartis AG; Bo Ying
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 23 added (5 new), 21 trimmed or exited. Largest new: Holocene Advisors $162.6M, Millennium Management $118.8M.
- AnalystsBULLISH
15 of 34 rate it Buy or better. Median target $158.50 (−1%).
- EstimatesRISING
Current-quarter EPS estimate $2.103 → $2.231 over 90 days. 1 up, 0 down in 30 days.
- Short sellersCOVERING
Short interest −19.1% to 4.52M shares. 1.9 days to cover, ≈0.2% of shares.
- TrendUPTREND
7% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 5.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GOLDMAN SACHS GROUP INC | TRIM | $467.1M |
| JPMORGAN CHASE & CO | ADD | $356.9M |
| WCM INVESTMENT MANAGEMENT, LLC | ADD | $300.1M |
| UBS Group AG | TRIM | $185.6M |
| Holocene Advisors, LP | NEW | $162.6M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $123.5M |
| DODGE & COX | NEAR_EXIT | $119.0M |
| MILLENNIUM MANAGEMENT LLC | NEW | $118.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
34 analystsPrice is inside the target range. Median implies −1%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 30, 2026 | Deutsche Bank DOWNGRADE | Sell |
| Sep 10, 2026 | HSBC UPGRADE | Hold |
Washington
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $2.23 | $2.19–$2.31 | +6.1% | $14.8B |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 1 bullish · 5 bearish · 2 mixed · 8 neutral- NEUTRAL 6-KNov 12, 2026
Novartis AG, through its subsidiary Novartis Capital Corporation, issued $5.5 billion aggregate…
Monitor Novartis's upcoming quarterly filings for use of proceeds and any change in leverage ratios. The $5.5B issuance is sizable but modest relative to a $311.5B market cap and the company's…
- NEUTRAL PTAB-TRIALNov 10, 2026
The PTAB granted institution of IPR2026-00260, allowing Amneal and Kashiv to challenge claims of…
Monitor the PTAB trial schedule and any related district court or ITC litigation for materiality. A final written decision finding claims unpatentable could affect Novartis's exclusivity for its…
- NEUTRAL 144Oct 28, 2026
Victor Bulto Carulla, an officer of Novartis AG, filed a Form 144 notice of intent to sell 6,000…
The proposed sale is small relative to the company's market cap and appears to be a routine insider transaction related to equity compensation. Monitor for any subsequent Form 4 filings to confirm…
- MIXED 6-KOct 27, 2026
Novartis reported Q3 2026 net sales of USD 14.5 billion (+4% cc) and core operating income of USD…
The raised core operating income guidance signals underlying business momentum from growth brands (Kisqali, Kesimpta, Scemblix, Leqvio) offsetting Entresto generic erosion. The del-desiran…
All NVS filing & press-release reports (16)
- 6-K reportNov 12, 2026
- PTAB-TRIAL reportNov 10, 2026
- 144 reportOct 28, 2026
- 6-K reportOct 27, 2026
- COURT-RULING reportOct 15, 2026
- COURT-RULING reportOct 13, 2026
- INST-CLUSTER reportSep 22, 2026
- 6-K reportSep 4, 2026
- 6-K reportSep 1, 2026
- COURT-RULING reportAug 4, 2026
- COURT-RULING reportJul 28, 2026
- 6-K reportJul 21, 2026
- COURT-RULING reportJul 1, 2026
- COURT-RULING reportApr 30, 2026
- COURT-RULING reportApr 14, 2026
- COURT-RULING reportMar 30, 2026